Why Elevidys Was Not Approved by the European Medicines Agency (EMA)?
The Elevidys (active substance: delandistrogene moxeparvovec) gene therapy was not approved by the European Medicines Agency (EMA) for the treatment of ambulatory children aged 3‑7...
Does Pulsed Electromagnetic Field (PEMF) Therapy Treat Duchenne Muscular Dystrophy and Initiate Dystrophin Production?
Duchenne Muscular Dystrophy (DMD) is a severe, inherited neuromuscular disorder that leads to progressive muscle weakness and degeneration. With limited treatment options available, many...
Could Axolotl’s Self Regenerative Ability Be Effective in Treating Duchenne Muscular Dystrophy?
Duchenne muscular dystrophy (DMD) is a severe X‑linked genetic disorder characterized by absence or dysfunction of dystrophin, a cytoskeletal protein essential for maintaining muscle...
Del-Zota DMD RNA Therapy from Avidity Biosciences Reverses the Progression of Disease
Due to the deaths of two patients following the use of Elevidys, a DMD gene therapy from Sarepta Therapeutics, the DMD community has had...
Support World Duchenne Awareness Day 2025 with DMDWarrior
World Duchenne Awareness Day will be observed globally on September 7, 2025, with the theme “Make Cures Affordable for Duchenne.” This important day raises...